Abstract| Volume 31, SUPPLEMENT 6, S153, November 1995

733 Randomised clinical study of Ukrain on colorectal cancer

      This paper is only available as a PDF. To read, Please Download here.
      Results from the National Cancer Institute (Bethesda, U.S.A.) showed that Ukrain (NSC 631570) has on human colorectal cell culture lines a more than 100-fold higher cytotoxic activity than broadly used 5fluorouracil (NSC 19893). In the EORTC study Ukrain was toxic to the colorectal cell lane CXF. That date gave us the basis for the next clinical study. In a randomised study 108 patients with advanced colorectal cancer, average 61.2 years, were included. 54 patients were treated with Ukrain as monotherapy and 54 with 5-fluororacil. The therapy results (clinical, haematological, immunological, biochemical) show that Ukrain has favourable properties in the treatment of colorectal cancer and clearly show advantages in contrary to 5-fluorouracil. Stability of the disease was reached in 88.8% and only 27.7% in the control group. The pretreatment with Ukrain facilitated the operability of the patients. The malignotoxic action of Ukrain in the clinic is confirmed by the results of pathomorphosis that gives more possibilities in operative treatment and increases the survival rate. Ukrain is a new effective drug in the therapy of colorectal cancer.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect